Retatrutide 2026 — the triple agonist that just changed everything.

On 21 May 2026, Eli Lilly announced the topline results of TRIUMPH-1 — the pivotal Phase 3 clinical trial of retatrutide 2026. The numbers stopped the obesity medicine field in its tracks. At the 12mg dose, participants lost an average of 28.3% of their body weight at 80 weeks. At 104 weeks, that figure reached 30.3%. More than 45% of participants on the highest dose lost 30% or more of their body weight — results comparable to bariatric surgery. Nothing in the history of non-surgical obesity treatment has produced numbers like these. Retatrutide 2026 is not just the next step in GLP-1 medicine — it is a category shift.

This guide covers everything UK patients need to know about retatrutide in 2026 — the complete TRIUMPH trial results, how it compares to Mounjaro and Wegovy, what the triple agonist mechanism means, and the realistic availability timeline for UK patients. All data is drawn from official Eli Lilly announcements, the NHS obesity treatment guidance, and peer-reviewed sources including the Pharmaceutical Journal analysis published 21 May 2026.

What is retatrutide?

Retatrutide (development code LY3437943) is an investigational once-weekly injectable developed by Eli Lilly — the same company that makes Mounjaro (tirzepatide). Where Mounjaro is a dual agonist activating GIP and GLP-1 receptors, retatrutide is a triple agonist — it activates three distinct metabolic receptors simultaneously: GIP, GLP-1, and glucagon.

This additional glucagon receptor activation is what makes retatrutide 2026 categorically different from every previous GLP-1 medication. Glucagon plays a central role in energy expenditure — it increases fat oxidation, raises metabolic rate, and amplifies the calorie-burning signal that GIP and GLP-1 produce. By adding glucagon receptor agonism to the dual GIP/GLP-1 mechanism of Mounjaro, retatrutide creates a more powerful and more comprehensive metabolic intervention than anything previously approved.

TRIUMPH-1 results — May 2026

TRIUMPH-1 is the pivotal Phase 3 obesity trial for retatrutide 2026 — 2,339 participants with obesity or overweight and at least one weight-related comorbidity, without diabetes, randomised to retatrutide 4mg, 9mg, or 12mg, or placebo. Results were announced by Eli Lilly on 21 May 2026:

To put these retatrutide 2026 numbers in context: the SURMOUNT-1 trial for Mounjaro showed 20.9% average weight loss at 72 weeks at the 15mg dose. TRIUMPH-1 showed 28.3% at 80 weeks at the 12mg dose — approximately 35% more weight loss than the current best-in-class approved medication. The 30.3% figure at 104 weeks is particularly significant: this is the territory of bariatric surgery outcomes, achieved with a weekly injection.

TRIUMPH-4 — osteoarthritis and beyond weight loss

Retatrutide 2026 data extends beyond pure weight loss. TRIUMPH-4, announced by Eli Lilly in December 2025, evaluated retatrutide in adults with obesity and knee osteoarthritis. The results were striking: at the highest dose, participants lost an average of 28.7% of body weight at 68 weeks alongside substantial and statistically significant reductions in knee pain scores and improvements in physical function. Cardiovascular risk markers — non-HDL cholesterol and systolic blood pressure — also improved significantly.

This positions retatrutide not merely as a weight loss drug but as a comprehensive metabolic intervention capable of addressing multiple obesity-related conditions simultaneously. Seven additional Phase 3 trials are expected to report results across 2026, including TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) — both of which will be critical for the regulatory submission.

Retatrutide vs Mounjaro vs Wegovy — 2026 comparison

The triple agonist mechanism explained

Understanding why retatrutide 2026 produces such dramatically superior results requires understanding what the glucagon receptor adds to the dual GIP/GLP-1 mechanism of Mounjaro:

• GLP-1 receptor activation: reduces appetite, slows gastric emptying, stimulates insulin secretion, suppresses glucagon — the foundation of all GLP-1 medications
• GIP receptor activation: enhances insulin secretion, improves beta cell function, and — through an additional mechanism — amplifies the appetite-reducing effect of GLP-1. This is what makes Mounjaro superior to semaglutide alone
• Glucagon receptor activation: the critical addition in retatrutide. Glucagon is the body’s primary energy-mobilising hormone. By activating glucagon receptors alongside GIP and GLP-1, retatrutide increases energy expenditure — the body burns more calories — and amplifies fat oxidation beyond what the appetite-suppressing mechanisms alone achieve. This is the mechanism responsible for the significant additional weight loss beyond Mounjaro

The progression is clear across the GLP-1 class: single agonism (semaglutide, ~14.9%), dual agonism (tirzepatide, ~20.9%), triple agonism (retatrutide, ~28.3%). Each additional receptor provides a meaningful and additive metabolic benefit.

Side effects from TRIUMPH Phase 3 data

The side effect profile of retatrutide 2026 from Phase 3 data is consistent with the GLP-1 medication class — primarily gastrointestinal effects that are most prominent during dose escalation and reduce over time:

• Nausea: the most common adverse event — typical incretin-associated gastrointestinal effect, predominantly during dose escalation phases
• Vomiting and diarrhoea: reported across doses, more common at higher doses
• Discontinuation rates: 4.1% at 4mg, 6.9% at 9mg, and 11.3% at 12mg — compared to 4.9% on placebo. The higher discontinuation rate at 12mg compared to Mounjaro’s Phase 3 data (5-7%) reflects the more potent effect at the highest dose
• Lean mass: data on lean mass and bone mineral density from TRIUMPH-1 has not yet been fully published. This is one of the most important outstanding questions for retatrutide given the magnitude of weight loss

UK availability timeline for retatrutide

For UK patients following the retatrutide 2026 story, the key dates and milestones:

• May 21, 2026: TRIUMPH-1 topline results confirmed — 28.3% weight loss at 80 weeks
• Q3–Q4 2026: TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (cardiovascular) results expected
• Q4 2026: Eli Lilly NDA filing with the FDA (confirmed on Q1 2026 earnings call)
• Late 2027: FDA approval expected (10–12 month review timeline)
• Q1–Q2 2028: US market launch anticipated
• 2028+: MHRA review and UK approval would follow FDA approval, likely with a lag of 6 to 12 months

Retatrutide is not currently MHRA approved in the UK. It is available from Mymetabolism as a research peptide for patients who wish to access it ahead of regulatory approval. Our HPLC-verified retatrutide preparations are tested to 99% purity with Certificates of Analysis on every batch. Browse our full product range including our current Retatrutide options, read our verified customer reviews, and see our complete What is Retatrutide guide for the full background on this medication.